Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mouse Models of Cancer Study

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

Mouse Models of Cancer Study

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026

Same author

Increasing power and robustness in screening trials by testing stored specimens in the control arm.

BMC medical research methodology·2026

Same author

Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.

JCO precision oncology·2026

Same author

Positive predictive value metrics for multicancer detection tests.

Journal of medical screening·2026

Same author

Comparing approaches to designing and accelerating evaluation of multicancer early detection tests.

Journal of the National Cancer Institute·2026

Same author

Endoscopic screening for colorectal cancer: efficacy versus effectiveness.

Journal of the National Cancer Institute·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens

Published on: April 27, 2011

Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute's Vanguard Study.

Elyse LeeVan¹, Amanda L Skarlupka¹, Christos Patriotis¹

¹Division of Cancer Prevention, US National Cancer Institute, Rockville, Maryland.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology

|August 4, 2025

Summary

The National Cancer Institute (NCI) developed a framework to evaluate multi-cancer detection (MCD) tests for future cancer screening trials. This process identified promising MCD assays for the Vanguard Study, prioritizing technologies for clinical research.

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues

Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues

Published on: March 29, 2021

Related Experiment Videos

Last Updated: Jun 15, 2026

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens

Published on: April 27, 2011

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues

Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues

Published on: March 29, 2021

Area of Science:

Oncology
Biotechnology
Clinical Trials

Background:

The National Cancer Institute (NCI) established the Cancer Screening Research Network (CSRN) to advance cancer detection research.
The inaugural CSRN study, the Vanguard Study, aims to evaluate the feasibility of multi-cancer detection (MCD) tests in randomized controlled trials.

Purpose of the Study:

To outline the NCI's framework for engaging MCD assay developers.
To describe the methodology for evaluating emerging MCD technologies using biobank reference sets.
To detail the selection process for fit-for-purpose MCD assays for the Vanguard Study.

Main Methods:

Engaged MCD assay developers and evaluated 23 diverse assays utilizing AI and machine learning.
Conducted blinded performance evaluations on nine assays using specimens from three biobanks.
Provided independent performance assessments to developers for assay refinement.

Main Results:

Two assay companies were selected to participate in the Vanguard Study following the evaluation process.
Assay developers utilized independent assessments to enhance the performance of their MCD tests.
The framework facilitated a transparent and fair evaluation of MCD assay performance.

Conclusions:

The NCI established a robust process for selecting promising MCD assays for clinical research and public health.
This assay selection framework can be adopted by other institutions and networks for prioritizing cancer screening technologies.
Efficient selection of high-performing technologies is crucial for resource-intensive large-scale cancer screening trials.